ADN-1184, a monoaminergic ligand with 5-HT\textsubscript{6/7} receptor antagonist action, exhibits activity in animal models of anxiety

Anna Partyka\textsuperscript{1} · Anna Wasik\textsuperscript{1} · Magdalena Jastrzębska-Więcek\textsuperscript{1} · Paweł Mierzejewski\textsuperscript{2} · Przemysław Bieńkowski\textsuperscript{2} · Marcin Kołaczkowski\textsuperscript{3,4} · Anna Wesołowska\textsuperscript{1}

Received: 7 December 2015 / Accepted: 7 March 2016 / Published online: 16 March 2016 © The Author(s) 2016. This article is published with open access at Springerlink.com

Abstract Behavioral and psychological symptoms of dementia (BPSD) include apathy, sleep problems, irritability, wandering, elation, agitation/aggression, and mood disorders such as depression and/or anxiety. Elderly patients are usually treated with second-generation antipsychotics; however, they present not enough efficacy against all symptoms observed. Hence, there still is an unmet need for novel pharmacotherapeutic agents targeted BPSD. A novel arylsulfonamide derivative ADN-1184 has been developed that possesses a preclinical profile of activity corresponding to criteria required for treatment of both psychosis and depressive symptoms of BPSD without exacerbating cognitive impairment or inducing motor disturbances. To broaden its pharmacological efficacy toward anxiety symptoms, its anxiolytic properties have been examined in common animal preclinical models in rats and mice. ADN-1184 significantly increased the number of entries into open arms measured in the elevated plus-maze test; however, it simultaneously increased parameters of exploratory activity. In the Vogel conflict drinking test, ADN-1184 dose-dependently and significantly increased the number of shocks accepted and the number of licks. Moreover, in mice, it also had specific anxiolytic-like activity in the four-plate test, and only negligible one at a specific mid-range dose measured in the spontaneous marble burying test. The obtained findings reveal that ADN-1184 displays anxiolytic-like activity in animal models of anxiety which employed punished stimuli. In its unusual combination of some anxiolytic action with already proven antipsychotic and antidepressant properties, and lack of any disruptive impact on learning and memory processes and motor coordination, ADN-1184 displays a profile that would be desired for a novel therapeutic for BPSD.

Keywords BPSD · Anxiety · Depression · Antipsychotic

Introduction

Dementia is a clinical syndrome that expresses itself in three areas, i.e., cognitive deficits, psychological and behavioral disturbances, and difficulties in carrying out daily functions (De Deyn and Wirshing 2001). Behavioral and psychological symptoms of dementia (BPSD) include apathy, sleep problems, irritability, wandering, elation, agitation/aggression, and mood disorders such as depression and/or anxiety. At least one symptom of BPSD is reported in about 80 % patients with dementia (Proitsi et al. 2011). The prevalence of anxiety is rated as 38 % in Alzheimer disease and up to 72 % in vascular dementia (Ballard et al. 2000).

BPSD affect the quality of life of older people and their caregivers. Pharmacological treatment ought to be considered when first-line non-pharmacological management fails or when there is a significant risk (e.g., physical aggression, agitation, or psychosis) (Cheung and Stapelberg 2011). Elderly patients are usually treated with second-generation antipsychotics (SGAs) that produce fewer extrapyramidal side-effects and have better efficacy against negative symptoms than classical neuroleptics (Byerly et al. 2001; Liperoti et al. 2008; Kołaczkowski et al. 2014b). Despite the global and...
embedded use of antipsychotics for BPSD treatment, the evidence and rationale for the use of this drug class is proven to be modest.

A recent meta-analysis based on 14 placebo-controlled trials of elderly patients with BPSD revealed only modest positive effects for risperidone, olanzapine, and aripiprazole, all SGAs (Maher et al. 2011). Moreover, SGAs may produce adverse effects including cardiovascular and metabolic ones (Nobili et al. 2009; Schulze et al. 2013). These drugs may also worsen cognitive function, especially in the case of elderly patients who already suffer from memory deficits (Jeste et al. 2008; Vigen et al. 2011). Some SGAs might be an option for the treatment of depressive symptoms (Moller 2000, 2005a, b; Leucht et al. 2013). These drugs may also worsen cognitive function, especially in the case of elderly patients who already suffer from memory deficits (Jeste et al. 2008; Vigen et al. 2011). Some SGAs might be an option for the treatment of depressive symptoms (Moller 2000, 2005a, b; Leucht et al. 2009); however, they were not developed to provide alleviation of mood deficits in elderly patients. There still is an unmet need for novel pharmacotherapeutic agents targeted for treatment of BPS—an increasingly challenging problem connected with the aging populations in many developed countries.

In Kołaczkowski et al. (2014a), we described a novel arylsulfonamide derivative (ADN-1184) that possesses a preclinical profile of activity corresponding to criteria required for treatment of both psychosis and depressive symptoms of BPSD without exacerbating cognitive impairment or inducing motor disturbances. As no animal model of BPSD is available, ADN-1184’s potential antipsychotic properties have been evaluated in a range of procedures, including hyperactivity and stereotypies induced by MK-801, procedures relevant to dementia patients who suffer from psychoses of glutamatergic origin (Bardin et al. 2007; Siegel 1978) as well as conditioned avoidance response (Kołaczkowski et al. 2014a). In all these models, ADN-1184 demonstrated an antipsychotic-like potency similar to or even stronger than that produced by SGAs and tested in the same experimental conditions (Kołaczkowski et al. 2014a). Moreover, ADN-1184 was also active in a classic model of potential antidepressant activity—the forced swim test—showing potency of the same order of magnitude as that of imipramine. Furthermore, its active antidepressant doses were lower than those in models of antipsychotic-like activity. Simultaneously, ADN-1184 did not impair the passive avoidance response in contrast to SGAs, which elicited dose-dependent disruption in that model. While being active in models of psychosis, mood deficit and memory performance, ADN-1184 additionally did not elicit catalepsy or a decrease in locomotor activity when administered at antipsychotic and antidepressant doses. ADN-1184 only began to decrease locomotor action at a dose of 30 mg/kg and, at the same dose, weakly elicited catalepsy (Kołaczkowski et al. 2014a).

ADN-1184 in vivo profile, combining antipsychotic- and antidepressant-like activities without cognitive or motor impairments, appears to stem from its unusual receptor combination resulting from potent blockade of 5-HT_6, 5-HT_7, and 5-HT_2A receptors, and modest antagonism of dopamine D_2 and D_3 receptors in the absence of anticholinergic effects. ADN-1184 also antagonizes α_1-adrenergic receptors which may contribute to its antipsychotic efficacy, widens the therapeutic window with regard to extrapyramidal side-effects (Wadenberg et al. 2000), and helps to reduce agitation and aggressive behavior (Wang et al. 2009) seen in elderly patients with BPSD. Antagonism of peripheral α_1-adrenergic receptors is associated with adverse cardiovascular effects, especially in elderly people; thus, this needs to be taken into consideration in the treatment of patients with potentially fragile cardiac function.

The above observations suggest that the combined multireceptor functional profile of ADN-1184 and its potential antipsychotic/antidepressant action observed in rats might offer an effective and broad-based platform for the control of mood deficit states. Inasmuch as anxiety is a common and comorbid symptom of depression, the present work discusses the potential anxiolytic-like activity of ADN-1184 detected in a wide range of rodent preclinical models of anxiety. Its activity has been compared to action of three SGAs (risperidone, olanzapine, and aripiprazole) for which small but statistically significant benefits have been observed in a recent meta-analysis (Maher et al. 2011) for the treatment of behavioral symptoms associated with dementia in elderly patients.

Materials and methods

Animals

The experiments were conducted on male Wistar rats (230–300 g) purchased from Charles River Laboratories (Germany) and male Albino Swiss mice (21–25 g) obtained from a licensed breeder (Staniszezewska, Poland). Animals were kept in a group of four (rats) or 10 (mice) in standard plastic cages and housed in a room under controlled conditions (temperature 21 ± 2 °C, humidity 50–60 %, under a 12-h light/dark cycle, lights on at 8.00 a.m.). Standard lab chow (Labofeed H, WPiK, Kcynia, Poland) and tap water were available ad libitum unless otherwise stated. All investigations were performed between 9:00 a.m. and 4:00 p.m. in soundproof experimental rooms under dim light and continuous white noise (65 dB). Behavioral parameters were recorded automatically by microcomputers or manually scored by observers unaware of the treatment applied. Tested animals were used only once. Treatment of animals in the present studies was in full accordance with the ethical standards laid down in respective Polish and European (Directive no. 86/609/EEC) regulations. All procedures were approved by a local ethics committee.
Drugs

ADN-1184 (hydrochloride salt), risperidone, olanzapine, and aripiprazole provided by Adamed Ltd. (Pienków, Poland), were suspended in a 1 % Tween 80 (Sigma-Aldrich) and administered intraperitoneally (i.p.) in a volume of 2 ml/kg (rats) or 10 ml/kg (mice). The drugs were injected 60 min (rats) or 30 min (mice) before the experiment. Control animals received vehicle according to the same procedure. All solutions were prepared immediately prior to use and protected from the light.

Behavioral procedures in rats

Elevated plus-maze (EPM) test

The testing procedure was based on a method described by Pellow and File (1986). EPM test is an “unconditional” anxiety-like test based on rodents’ natural aversion to heights and open spaces. Plus-maze apparatus (an automated device produced by Campden Instruments Ltd. (UK) made of durable, high density, non-porous black plastic, elevated to a height of 50 cm, consisted of two open arms (50 × 10 cm) and two closed arms (50 × 10 cm, and 30-cm high walls), arranged so that the two arms of each type were opposite each other. Floor of the plus-maze was made of infrared transparent material what means that there are no visible sensors. Plus-maze apparatus was connected to PC software by control chassis. The experiments were conducted under dim light (only the center of the maze was illuminated with low-intensity light 30 lux measured on the maze level) and continuous white noise (65 dB). Each rat was gently placed in the center of the plus-maze, facing one of the closed arms, immediately after a 5-min adaptation period in a plastic black box (60 × 60 × 35 cm), to increase the overall activity in the EPM. During a 5-min test period, automated Motor Monitor System recorded the number of entries into the closed and open arms and the time spent in either type of the arms. The device counted an effective arm-entry when the four paws of a rat were into any arm. The maze was thoroughly cleaned after each trial.

Exploratory activity measured in the EPM test

To assess an influence of a tested compound on general exploratory activity of rats and to control possible changes within, total ambulation (the total distance covered by a rat, and ambulation along X and Y axis) was taken during a 5-min test period (i.e., the time equal to the observation period in the EPM test). The experiment was performed using EPM apparatus (details see above).

Vogel conflict drinking test

The testing procedure based on a method described by Vogel et al. (1971) was performed using Anxiety Monitoring System “Vogel test” produced by TSE Systems. Apparatus was consisted of a polycarbonate cage (dimensions 26.5 _15 _ 42 cm), equipped with a grid floor made from stainless steel bars and a drinking bottle containing tap water. Experimental chambers (two) were connected to PC software by control chassis and a device that generates electric shocks. In this “conditional” model, an electric shock as noxious stimulus is applied. The testing procedure consisted of 2-day habituation/adaptation and an exact test. On the first day of the experiment, the rats were adapted to the test chamber for 10-min adaptation period during which they had free access to the drinking bottle followed by a 24-h water deprivation period. Afterwards, they were allowed a 30-min free-drinking session in their home cages. This protocol of 24-h deprivation and adaptation period was repeated on the second day. On the third day, animals were place again in the test chamber 60 min after administration of vehicle/ADN-1184 and were given free access to drinking bottle during 5 min. Recording the data started immediately after the first lick, and every 20 licks rats were punished with an electric shock (0.5 mA, lasting 1 s). The impulses were released via the spout of the drinking bottle. The number of licks and the number of shocks received throughout a 5-min experimental session were recorded automatically.

Hot plate and free-drinking tests

To exclude possible drug-induced changes in shock sensitivity or an increasing influence on thirst drive which can lead to false positive results in the Vogel conflict drinking test, stimulus threshold and water consumption during a free-drinking session were determined in separate groups of rats. In either of those two studies, the rats were manipulated similarly to the Vogel conflict drinking test, including two 24-h water deprivation periods separated by 10-min adaptation session in experimental cages and 30-min of water availability in their home cages. In the free-drinking test, each animal was allowed to freely drink from the drinking bottle and the amount of water (g) consumed during 5 min was recorded for each rat. The pain threshold was evaluated using hot plate test (Comnat Ltd, Turkey) in rats. The plate was enclosed with a transparent Plexiglass cylinder (35-cm high) to keep the animal on the heated surface of the plate. The latency to pain reaction (lick a hind paw or jumping) when the rat was placed on a hot plate (52.5±0.5 °C, 19-cm diameter) was measured. The rat was removed from the plate immediately upon visible pain reaction or if no response occurred within 30 s.
Four-plate test (4-PT)

The four-plate apparatus (BIOSEB) consists of a cage (25 × 18 × 16 cm) floored by four identical rectangular metal plates (8 × 11 cm) separated from one another by a gap of 4 mm. The top of the cage is covered by a transparent Perspex lid that prevents escape behavior. The plates are connected to a device that can generate electric shocks. Following a 15-s habituation period, the animal’s motivation to explore a novel environment is suppressed by an electric foot shock (0.8 mA, 0.5 s) every time it moves from one plate to another during a 1-min test session. This action is referred to as a punished crossing and is followed by a 3-s shock interval, during which the animal can move across plates without receiving a shock (Aron et al. 1971).

Marble burying test (MBT)

The test was performed based on a method described by Broekkamp et al. (1986) with minor modifications. Mice were placed individually into plastic cages which were identical to their home cage containing a 5-cm layer of sawdust and 20 marbles (1.4-cm diameter) evenly spaced against the wall. After 30-min experimental period, mice were removed from cages and the number of marbles at least 2/3 buried was counted. The experiment was conducted on Albino Swiss mice.

Data analysis

All the data are presented as the mean ± SEM. The statistical significance of the results was evaluated by a one-way analysis of variance (ANOVA), followed by Bonferroni’s comparison test (statistical significance set at p < 0.05). The data from the hot plate and free-drinking test was analyzed using a t test. The Statistica 10.0 software package for Windows (StatSoft, Tulsa, OK, USA) was used to analyze all data.

Results

EPM test

Table 1  Anxiolytic-like effects of the tested compounds in the EPM test in rats

| Treatment                  | Dose (mg/kg) | Time (s) spent in the open arms | Percentage of time spent in the open arms | Number of entries into the open arms | Percentage of entries into the open arms |
|----------------------------|--------------|---------------------------------|------------------------------------------|-------------------------------------|----------------------------------------|
| Vehicle ADN-1184           | 0            | 49.2 ± 7.4                      | 25.7 ± 3.5                               | 10.6 ± 2.0                          | 31.6 ± 5.1                             |
|                            | 0.1          | 68.6 ± 6.3                      | 34.0 ± 5.4                               | 13.1 ± 1.4                          | 32.5 ± 4.4                             |
|                            | 0.3          | 87.8 ± 11.4                     | 44.0 ± 4.8                               | 18.2 ± 2.2*                         | 37.8 ± 2.8                             |
|                            | 1            | 78.3 ± 2.4                      | 36.0 ± 5.6                               | 15.3 ± 1.6                          | 37.8 ± 3.9                             |
|                            | 3            | 73.5 ± 15.1                     | 35.3 ± 2.9                               | 11.0 ± 1.0                          | 45.6 ± 4.6                             |
| Vehicle Risperidone        | 0            | 43.1 ± 10.1                     | 19.0 ± 4.9                               | 8.5 ± 2.8                           | 21.2 ± 4.5                             |
|                            | 0.03         | 78.5 ± 11.3                     | 33.6 ± 5.1                               | 14.8 ± 2.1                          | 38.0 ± 2.7*                            |
|                            | 0.1          | 79.9 ± 8.9                      | 33.1 ± 3.7                               | 16.0 ± 1.7                          | 37.3 ± 2.4*                            |
|                            | 0.3          | 95.1 ± 19.4                     | 40.4 ± 8.2                               | 12.7 ± 2.1                          | 36.4 ± 4.8                             |
| Vehicle Olanzapine         | 0            | 84.3 ± 19.6                     | 33.0 ± 7.5                               | 13.0 ± 1.8                          | 35.5 ± 5.3                             |
|                            | 0.03         | 50.0 ± 12.8                     | 19.8 ± 5.2                               | 7.8 ± 1.1                           | 29.1 ± 3.4                             |
|                            | 0.1          | 94.8 ± 9.0                      | 40.1 ± 4.4                               | 16.3 ± 2.6                          | 37.0 ± 6.0                             |
|                            | 0.3          | 71.3 ± 12.3                     | 27.8 ± 5.1                               | 11.9 ± 2.4                          | 40.5 ± 3.9                             |
| Vehicle Aripiprazole       | –            | 97.3 ± 20.6                     | 40.4 ± 8.6                               | 17.6 ± 4.0                          | 39.0 ± 6.9                             |
|                            | 0.3          | 123.8 ± 13.5                    | 52.5 ± 4.7                               | 18.8 ± 2.2                          | 52.2 ± 4.5                             |
|                            | 1            | 75.5 ± 14.7                     | 32.6 ± 6.2                               | 13.7 ± 1.9                          | 36.4 ± 5.0                             |
|                            | 3            | 89.5 ± 36.4                     | 33.5 ± 12.3                              | 9.5 ± 1.8                           | 33.0 ± 4.1                             |
| F(3,25) = 2.515, NS        | F(3,25) = 2.521, NS              | F(3,25) = 3.070, p < 0.05                | F(3,25) = 1.183, NS                 |

ADN-1184, risperidone, olanzapine, and aripiprazole were injected i.p. 60 min before the test. Values represent the mean ± SEM during the 5-min test session compared with vehicle group *p < 0.05 (ANOVA is followed by the Bonferroni’s post hoc test), N = 5–8

Behavioral procedures in mice

Four-plate test (4-PT)

The four-plate apparatus (BIOSEB) consists of a cage (25 × 18 × 16 cm) floored by four identical rectangular metal plates (8 × 11 cm) separated from one another by a gap of 4 mm. The top of the cage is covered by a transparent Perspex lid that prevents escape behavior. The plates are connected to a device that can generate electric shocks. Following a 15-s habituation period, the animal’s motivation to explore a novel environment is suppressed by an electric foot shock (0.8 mA, 0.5 s) every time it moves from one plate to another during a 1-min test session. This action is referred to as a “punished crossing” and is followed by a 3-s shock interval, during which the animal can move across plates without receiving a shock (Aron et al. 1971).

Marble burying test (MBT)

The test was performed based on a method described by Broekkamp et al. (1986) with minor modifications. Mice were placed individually into plastic cages which were identical to their home cage containing a 5-cm layer of sawdust and 20 marbles (1.4-cm diameter) evenly spaced against the wall. After 30-min experimental period, mice were removed from cages and the number of marbles at least 2/3 buried was counted. The experiment was conducted on Albino Swiss mice.
aripiprazole produced no significant effects in that test; however, a tendency to increase the number of entries into open arms and the percentage of entries into the open arms, respectively, was observed (Table 1).

Exploratory activity measured in the EPM test

Both parameters, i.e., total entries and total distance travelled presented in Table 2, measured simultaneously with anxiolytic-like activity using the automated version of the EPM, reflect general exploratory activity of rats. ADN-1184 at doses of 0.1, 0.3, and 1 mg/kg significantly increased one or two of parameters measured. The tested compound administered at a dose of 3 mg/kg had no influence on general exploratory activity. Similarly, all tested SGAs did not affect exploratory activity of rats measured in EPM (Table 2).

Vogel conflict drinking test

ADN-1184 at a dose of 3 mg/kg significantly increased the number of shocks accepted (ANOVA $F(3,25) = 5.391$, $p<0.01$) and the number of licks (ANOVA $F(3,25) = 5.761$, $p<0.01$) during 5-min experimental evaluation. Lower doses of ADN-1184, i.e., 0.3 and 1 mg/kg were ineffective in that test but the measured effect was dose-dependent (Figs. 1a and 2a). Risperidone at a dose of 0.03 mg/kg (ANOVA $F(2,28) = 3.504$, $p<0.01$ and $F(2,28) = 3.454$, $p<0.01$), olanzapine at doses of 1 and 3 mg/kg (ANOVA $F(3,31) = 4.248$, $p<0.05$ and $F(3,31) = 4.159$, $p<0.05$) and aripiprazole at a dose of 10 mg/kg (ANOVA $F(3,23) = 6.079$, $p<0.01$ and $F(3,23) = 5.922$, $p<0.01$) significantly increased the number of shocks accepted and the number of licks measured in the Vogel test, respectively (Figs. 1b–d and 2b–d).

Hot-plate and free-drinking tests

ADN-1184, risperidone, olanzapine, and aripiprazole administered at doses effective in the Vogel conflict drinking test, i.e., 3, 0.03, 1, 3, and 10 mg/kg, respectively, had no effect on pain reaction time measured in the hot plate test as well as they did not change the amount of water consumed by deprived rats as compared with control animals, during 5-min session (Table 3).

4-PT

ADN-1184 given at doses of 0.312, 0.625, and 1.25 mg/kg, dose-dependently and significantly increased the number of punished crossings (ANOVA $F(4,42) = 5.023$, $p<0.01$). There was no difference between control group and the dose 0.156 mg/kg of ADN-1184 (Fig. 3a). Risperidone at doses of

| Treatment             | Dose (mg/kg) | Total entries | Total distance [cm] |
|-----------------------|--------------|---------------|---------------------|
| Vehicle ADN-114        | 0            | 29.0±2.4      | 4613.0±158.0        |
|                       | 0.1          | 40.6±3.5      | 5686.6±201.1*       |
|                       | 0.3          | 49.3±4.5**    | 5544.5±245.7**      |
|                       | 1            | 41.8±3.9**    | 5519.0±282.6        |
|                       | 3            | 25.9±2.6      | 3777.9±401.1        |
|                       | $F(4,29) = 7.853$, $p<0.001$ | $F(4,29) = 11.292$, $p<.0001$ |
| Vehicle Risperidone   | 0            | 35.5±7.0      | 4465.3±462.0        |
|                       | 0.03         | 39.9±5.5      | 5268.0±416.0        |
|                       | 0.1          | 42.9±3.7      | 5072.5±318.0        |
|                       | 0.3          | 35.1±4.7      | 4524.7±259.9        |
|                       | $F(3,25) = 0.516; NS$ | $F(3,25) = 1.156; NS$ |
| Vehicle Olanzapine    | 0            | 38.2±2.6      | 5078.7±157.7        |
|                       | 0.03         | 26.6±1.9      | 4552.5±198.0        |
|                       | 0.1          | 43.4±5.8      | 5401.1±448.4        |
|                       | 0.3          | 30.6±6.1      | 4591.6±355.2        |
|                       | $F(3,25) = 2.680$, $NS$ | $F(3,25) = 1.653$, $NS$ |
| Vehicle Aripiprazole  | 0            | 43.4±6.7      | 5613.8±222.9        |
|                       | 0.3          | 32.2±6.5      | 4419.0±467.4        |
|                       | 1            | 38.4±2.5      | 4792.0±132.9        |
|                       | 3            | 35.5±2.8      | 4641.8±260.9        |
|                       | $F(3,22) = 0.960$, $NS$ | $F(3,22) = 2.651$, $NS$ |

ADN-1184, risperidone, olanzapine and aripiprazole were injected i.p. 60 min before the test. Values represent the mean ± SEM during the 5-min test session compared with vehicle group *$p<0.05$ (ANOVA is followed by the Bonferroni’s post hoc test), $N=6–8$.

Table 2 Effects of the tested compounds on exploratory activity measured in the EPM in rats

| Treatment             | Dose (mg/kg) | Total entries | Total distance [cm] |
|-----------------------|--------------|---------------|---------------------|
| Vehicle ADN-114        | 0            | 29.0±2.4      | 4613.0±158.0        |
|                       | 0.1          | 40.6±3.5      | 5686.6±201.1*       |
|                       | 0.3          | 49.3±4.5**    | 5544.5±245.7**      |
|                       | 1            | 41.8±3.9**    | 5519.0±282.6        |
|                       | 3            | 25.9±2.6      | 3777.9±401.1        |
|                       | $F(4,29) = 7.853$, $p<0.001$ | $F(4,29) = 11.292$, $p<.0001$ |
| Vehicle Risperidone   | 0            | 35.5±7.0      | 4465.3±462.0        |
|                       | 0.03         | 39.9±5.5      | 5268.0±416.0        |
|                       | 0.1          | 42.9±3.7      | 5072.5±318.0        |
|                       | 0.3          | 35.1±4.7      | 4524.7±259.9        |
|                       | $F(3,25) = 0.516; NS$ | $F(3,25) = 1.156; NS$ |
| Vehicle Olanzapine    | 0            | 38.2±2.6      | 5078.7±157.7        |
|                       | 0.03         | 26.6±1.9      | 4552.5±198.0        |
|                       | 0.1          | 43.4±5.8      | 5401.1±448.4        |
|                       | 0.3          | 30.6±6.1      | 4591.6±355.2        |
|                       | $F(3,25) = 2.680$, $NS$ | $F(3,25) = 1.653$, $NS$ |
| Vehicle Aripiprazole  | 0            | 43.4±6.7      | 5613.8±222.9        |
|                       | 0.3          | 32.2±6.5      | 4419.0±467.4        |
|                       | 1            | 38.4±2.5      | 4792.0±132.9        |
|                       | 3            | 35.5±2.8      | 4641.8±260.9        |
|                       | $F(3,22) = 0.960$, $NS$ | $F(3,22) = 2.651$, $NS$ |
0.005 and 0.01 mg/kg produced anxiolytic-like activity measured in that test (ANOVA $F(2,23)=4.963$, $p<0.05$) while higher doses significantly decreased the number of punished crossings (ANOVA: $F(3,36)=9.013$, $p<0.0001$) (Fig. 3b). Olanzapine tested at doses of 0.25–2 mg/kg (ANOV A $F(4,53)=3.123$, $p<0.05$) and aripiprazole at doses of 0.06–0.5 mg/kg (ANOVA $F(4,49)=4.856$, $p<0.01$) produced no statistical anxiolytic-like effect in that test. In the case of aripiprazole, a tendency to increase the number of punished crossings could be observed; however, the results did not reach significant level (Fig. 3c, d).

**Discussion**

ADN-1184, a novel monoaminergic ligand with antipsychotic and antidepressant activities (Kolaczkowski et al. 2014a), possesses a multitarget profile distinct from current atypical antipsychotic agents. Its dopamine D$_2$ and D$_3$ antagonist properties, together with its potent blockade of 5-HT$_6$, 5-HT$_7$ and 5-HT$_2A$ receptors, and the absence of anticholinergic and antihistaminic effects, are consistent with a beneficial influence on psychosis, cognition, and mood impairments. Inasmuch as anxiety is a common and comorbid symptom of BPSD, we examined the potential action of ADN-1184 in common rodent models of anxiety to broaden its behavioral profile. We used different anxiety procedures based on a variety of anxiety stimuli. The EPM test is postulated to induce unconditioned fear due to heights and open spaces, which seems to be consistent with panic anxiety (Graeff et al. 1996). In this model, ADN-1184 increased all parameters measured; however, it only significantly increased the number of entries into open arms after administration at a dose of 0.3 mg/kg. Simultaneously, that dose of ADN-1184 increased parameters of exploratory activity indicating that this is likely accounted for the increased number of entries into the open arms.

Generalized anxiety disorder, a common, undertreated yet incapacitating disorder reveals a chronic prognosis and is
frequently comorbid with other symptoms of BPSD (Liperoti et al. 2008). This anxiety state is probably linked to a bias in anticipating adverse circumstances, often without any obvious threat (Steimer 2011). There are few, if any, animal models sufficiently validated to discriminate among the various subtypes of anxiety disorders. In general, operant conflict procedures are pharmacologically isomorphic with the human state of generalized anxiety (Schlaepfer and Nemeroff 2012).

Among these conditioned procedures, the Vogel test is of rather broad significance to clinical anxiety, particularly to generalized anxiety disorder (Millan and Brocco 2003). The anxiolytic-like activity of ADN-1184 is clearly visible in the Vogel conflict drinking test in rats, a "conditional" anxiety-like paradigm. ADN-1184 dose-dependently and significantly increased the number of shocks accepted and the number of licks. Moreover, it presented specific anti-conflict action, since ADN-1184 had an effect on neither the pain threshold nor unpunished water consumption. ADN-1184 also had specific anxiolytic-like activity in the FPT and only a negligible effect in the MBT visible at a specific mid-range dose. Thus, it appears that ADN-1184 clearly exerts the anxiolytic-like effect in tests incorporating punishing stimuli; however, it produces little or no effect in models based on innate anxiety in the EPM or anxiety/compulsive-like behavior in the MBT.

In the present study, we compared the action of ADN-1184 with the effects produced by three SGAs—olanzapine, risperidone, and aripiprazole were injected i.p. 60 min before the test. Values represent the mean ± SEM compared to the respective vehicle groups *p < 0.05; **p < 0.001 (ANOVA is followed by the Bonferroni’s post hoc test), N = 7–8

### Table 3 Effects of the tested compounds in the hot plate and water consumption tests in water-deprived rats

| Treatment  | Dose (mg/kg) | Hot plate test | Water consumption (g/5 min) |
|------------|--------------|----------------|-----------------------------|
| Vehicle    | 0            | 8.1 ± 0.7      | 5.3 ± 0.3                   |
| ADN-1184   | 3            | 7.8 ± 0.9      | 5.6 ± 0.3                   |
| Risperidone| 0.03         | 7.1 ± 0.7      | 5.7 ± 0.9                   |
| Olanzapine | 1            | 8.4 ± 0.8      | 5.1 ± 0.4                   |
|            | 3            | 8.6 ± 0.6      | 5.6 ± 0.5                   |
| Aripiprazole| 10          | 7.5 ± 0.8      | 5.4 ± 0.9                   |

ADN-1184, risperidone, olanzapine and aripiprazole were injected i.p. 60 min before the test. Values represent the mean ± SEM of time reaction in the hot plate test and amount of water consumed during 5 min test session. The data were analyzed using *t* test and *one-way ANOVA followed by Bonferroni’s post hoc test, N = 7–8
aripiprazole, and risperidone—since the recent meta-analysis had revealed that all these drugs produced a small but significant improving effect on behavioral symptoms of dementia in elderly patients (Maher et al. 2011). It is noteworthy that, quantitatively, ADN-1184 was more efficacious in the FPT in mice than olanzapine and aripiprazole studied under the same conditions. However, in the EPM or MBT, it had no appreciable effect but risperidone does or olanzapine and aripiprazole do, respectively. In the rat Vogel model, ADN-1184 showed superiority over aripiprazole when one considers the active dose of both compounds. However, when the magnitude of change is taken into account, the studied compound did not present better parameters than the reference antipsychotic drugs. Furthermore, anxiolytic-like activity of ADN-1184 in both rats and mice was 10 to 30-fold weaker than that of risperidone acting in low doses; however, risperidone has greater potency to induce adverse effects, e.g., catalepsy and sedation, than ADN-1184 (Kołaczkowski et al. 2014a, b). These data deliver indications of accentuated anxiolytic-like activity of ADN-1184, especially in models employing punished stimuli; however, drawing definite conclusions about its clinical potency is premature. Generally, animal tests and in this case, animal models of anxiety can certainly be useful to find out more about a pharmacological profile of newly developed compounds and biological bases of anxiety disorders. These models certainly provide a lot of information on the brain and behavioral mechanisms which could be involved in the etiology and physiopathology of anxiety disorders, but are usually not satisfactory when confronted directly with clinical syndromes (Steimer 2011).

The neurobiological mechanisms that mediate the anxiolytic-like action of ADN-1184 are not clear. Since ADN-1184, similar to most SGAs, has a complex multiple-receptor binding profile, it is difficult to pinpoint which receptor action or actions account for its anxiolytic-like activity. Nevertheless, given the in vitro pharmacological profile of ADN-1184, it seems that 5-HT6 and/or 5-HT7 receptor antagonism is most probably involved in the anxiolytic-like effects of this compound. Indeed, it was previously shown that both the selective 5-HT6 and the selective 5-HT7 receptor antagonists displayed pronounced anti-anxiety effects, in the same animal models as the ones used for characteristic of ADN-1184 (Wesołowaska and Nikiforuk 2007; Wesołowaska et al. 2006). Furthermore, the described effects of 5-HT6 receptor blockade were more pronounced and were suggested to be connected with indirect enhancement of GABA-ergic transmission (Wesołowaska 2008). Future research should be directed at clarifying this issue.
In conclusion, the obtained findings reveal that ADN-1184 displays anxiolytic-like activity in animal models of anxiety which employed punished stimuli. In its unusual combination of some anxiolytic action with already proven antipsychotic and antidepressant properties, and lack of any disruptive impact on learning and memory processes and motor coordination, ADN-1184 displays a profile, that would be desired for a novel therapeutic for BPSD. Additionally, considering any further development of pharmacotherapeutics to treat BPSD, one should bear in mind that the use of antipsychotic drugs in BPSD is limited by boxed warnings issued by the US Food and Drug Administration. The warnings added to the package inserts of SGAs emphasize the risk of serious adverse effects that can be induced by these drugs in elderly patients (Schneider et al. 2006; Schulze et al. 2013). Hence, meeting the need for efficacious medications to treat BPSD would require a continuous discussion between preclinical and clinical researchers as well as regulatory bodies and development of guidelines indicating strategies for evaluation of novel compounds with safer therapeutic profiles (Kołaczkowski et al. 2014a).

Acknowledgments The study was financially supported by Adamed Ltd., NCBiR, Warsaw, Poland (project no. KB/88/12655/TT1-C/U/08), and funds for Statutory Activity of the Jagiellonian University Medical College, Cracow, Poland (K/ZDS/004121).

Compliance with ethical standards

Ethical approval All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. All the experimental procedures performed in studies involving animals were approved by the IV Local Ethics Commission in Warsaw (no. 40/2008) and I Local Ethics Commission in Cracow (119/2013), and were in accordance with the 1996 NIH Guide for the Care and Use of Laboratory Animals.

Conflict of interest The authors declare that they have no conflict of interest. Marcin Kołaczkowski is an employee of Adamed Ltd.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

Aron C, Simon P, Larousse C, Boissier JR (1971) Evaluation of a rapid technique for detecting minor tranquilizers. Neuropharmacology 10: 459–469
Ballard C, Neill D, O’Brien J et al (2000) J Affect Disord 59:97–106
Bardin L, Auclair A, Kleven MS et al (2007) Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics. Behav Pharmacol 18:103–118

Broekkamp CL, Rijk HW, Joly-Gelouin D, Lloyd KL (1986) Major tranquilizers can be distinguished from minor tranquilizers on the basis of effects on marble burying and swim-induced grooming in mice. Eur J Pharmacol 126:223–229

Byerly MJ, Weber MT, Brooks DL et al (2001) Antipsychotic medications and the elderly: effects on cognition and implications for use. Drugs Aging 18:45–61

Cheung G, Stapelberg J (2011) Quetiapine for the treatment of behavioural and psychological symptoms of dementia (BPSD): a meta-analysis of randomised placebo-controlled trials. N Z Med J 124:39–50

De Deyn P, Wirshing W (2001) Scales to assess efficacy and safety of pharmacological agents in the treatment of behavioral and psychological symptoms of dementia. J Clin Psychiatry 62:19–22

Gnaeff FG, Guimar es FS, De Andrade TGCS et al (1996) Role of 5-HT in stress, anxiety, and depression. Pharmacol Biochem Behav 54:129–141

Jeste DV, Blazer D, Casey D et al (2008) ACNP white paper: update on antipsychotics for the treatment of behavioral and psychological symptoms of dementia. Neuropharmacology 57:160–170

Kołaczkowski M, Mierzejewski P, Bienkowski P et al (2014a) ADN 1184 a monoaminergic ligand with 5-HT6 receptor antagonist activity: pharmacological profile and potential therapeutic utility. Br J Pharmacol 171:973–984

Kołaczkowski M, Mierzejewski P, Bienkowski P et al (2014b) Antipsychotic, antidepressant, and cognitive-impairment properties of antipsychotics: rat profile and implications for behavioral and psychological symptoms of dementia. Naunyn Schmiedeberg’s Arch Pharmacol 387:545–557

Leucht S, Corves C, Arbiter D et al (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373:31–41

Liperoti R, Pedone C, Corsonello A (2008) Antipsychotics for the treatment of behavioral and psychological symptoms of dementia (BPSD). Curr Neuropharmacol 6:117–124

Maher AR, Maglione M, Bagley S et al (2011) Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA 306:1359–1369

Millan MJ, Brocco M (2003) The Vogel conflict test: procedural aspects, γ-aminobutyric acid, glutamate and monoamines. Eur J Pharmacol 463:67–96

Moller H-J (2000) Definition, psychopharmacological basis and clinical evaluation of novel/atypical neuroleptics: methodological issues and clinical consequences. World J Biol Psychiatry 1:75–91

Moller H-J (2005a) Antidepressive effects of traditional and second-generation antipsychotics: a review of the clinical data. Eur Arch Psychiatry Clin Neurosci 255:83–93

Moller H-J (2005b) Antipsychotic and antidepressive effects of second-generation antipsychotics. Eur Arch Psychiatry Clin Neurosci 255:190–201

Nobili A, Pasina L, Trevisan S et al (2009) Use and misuse of antipsychotic drugs in patients with dementia in Alzheimer special care units. Int Clin Psychopharmacol 24:97–104

Pellow S, File SE (1986) Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat. Pharmacol Biochem Behav 24:525–529

Protsi P, Hamilton G, Tosalik M et al (2011) A multiple indicators multiple causes (MIMIC) model of behavioural and psychological symptoms in dementia (BPSD). Neurobiol Aging 32:434–442

Schlaepfer TS, Nemeroff CB (2012) Neurobiology of psychiatric disorders. 1st edn. Handbook of clinical neurology, vol. 106

Schneider LS, Dagerman K, Insel PS (2006) Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatr 14:191–210

Schulze J, van den Bussche H, Glashe G et al (2013) Impact of safety warnings on antipsychotic prescriptions in dementia: nothing has changed but the years and the substances. Eur Neuropsychopharmacol 23:1034–1042

Siegell RK (1978) Phencyclidine and ketamine intoxication: a study of four populations of recreational users. NIDA Res Monogr 21:119–147

Steimer T (2011) Animal models of anxiety disorders in rats and mice: some conceptual issues. Dialogues Clin Neurosci 13:495–506

Vigen CL, Mack WI, Keefe RS et al (2011) Cognitive effects of atypical antipsychotic medications in patients with Alzheimer’s disease: outcomes from CATIE-AD. Am J Psychiatry 168:831–9. doi:10.1176/appi.ajp.2011.08121844

Vogel JR, Beer B, Clody DE (1971) A simple and reliable conflict procedure for testing anti-anxiety agents. Psychopharmacologia 21:1–7

Wadenberg ML, Hertel P, Fernholm R et al (2000) Enhancement of antipsychotic-like effects by combined treatment with the alpha1-adrenoceptor antagonist prazosin and the dopamine D2 receptor antagonist raclopride in rats. J Neural Transm 107:1229–1238

Wang LY, Shofer JB, Rohde K et al (2009) Prazosin for the treatment of behavioral symptoms in patients with Alzheimer’s disease with agitation and aggression. Am J Geriatr Psychiatr 17:744–751

Wesolowska A (2008) The anxiolytic-like effect of the selective 5-HT6 receptor antagonist SB-399885: the impact of benzodiazepine receptors. Eur J Pharmacol 580:355–260

Wesolowska A, Nikiforuk A (2007) Effects of the brain-penetrant and selective 5-HT6 receptor antagonist SB-399885 in animal models of anxiety and depression. Neuropharmacology 52:1274–1283

Wesolowska A, Nikiforuk A, Stachowicz K et al (2006) Effect of the selective 5-HT7 receptor antagonist SB 269970 in animal models of anxiety and depression. Neuropharmacology 51:578–586